Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2070132 | 0.80 | SLC6A4 (0.44) | SLC6A4SLC6A2SLC6A3SMN1; SMN2RAB9A | |
| SCHEMBL2069658 | 0.77 | SLC6A4 (0.67) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL2069078 | 0.73 | CNR1 (0.43) | — | |
| SCHEMBL2069794 | 0.73 | PPARA (0.41) | KCNH2 | |
| SCHEMBL2069069 | 0.72 | PPARA (0.46) | SMN1; SMN2RAB9ANPC1KDM4EPOLB | |
| SCHEMBL2069539 | 0.72 | PPARA (0.46) | SMN1; SMN2RAB9ANPC1KDM4EPOLB | |
| SCHEMBL2069858 | 0.71 | PPARA (0.52) | CHEK1SMN1; SMN2RAB9ANPC1KDM4E | |
| SCHEMBL2069857 | 0.71 | PPARA (0.52) | CHEK1SMN1; SMN2RAB9ANPC1KDM4E | |
| SCHEMBL2070322 | 0.71 | PPARA (0.45) | MAPT | |
| SCHEMBL2069137 | 0.70 | PPARA (0.66) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101189231-B | Novel cyclic aminophenylalkanoic acid derivative | KYORIN SEIYAKU KK | 2011-05-18 | — | — | CN | disclosed |
| US-7902367-B2 | Cyclic amino benzoic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20090036489-A1 | Novel Cyclic Aminophenylalkanoic Acid Derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| CN-101189231-A | Novel cyclic aminophenylalkanoic acid derivative | KYORIN SEIYAKU KK (JP) | 2008-05-28 | — | — | CN | disclosed |
| US-20070249580-A1 | Novel Cyclic Amino Benzoic Acid Derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| CN-101014595-A | Novel cyclic aminobenzoic acid derivative | KYORIN SEIYAKU KK (JP) | 2007-08-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036489-A1 | Novel Cyclic Aminophenylalkanoic Acid Derivative | PPARA, PPARD, PPARG | SLC6A4 1503/4885CHEK1 4309/4885SLC6A2 2830/4885 |
| US-20070249580-A1 | Novel Cyclic Amino Benzoic Acid Derivative | PPARA, PPARG, PPARD | SLC6A4 1813/4885CHEK1 3290/4885SLC6A2 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.